Regeneron Pharmaceuticals Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of ill...
Latest News
10 hours ago · benzinga.com
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 ResultsRegeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.
11 hours ago · benzinga.com
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For MondayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
2 days ago · fool.com
Regeneron: 3 Key Takeaways for Long-Term InvestorsDupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.
3 days ago · zacks.com
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock UpRegeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
3 days ago · seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call TranscriptRegeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
3 days ago · seekingalpha.com
Regeneron Is Just Getting StartedRegeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed resilience despite biosimilar competition; pipeline updates further reinforced Regeneron's momentum. I now expect 2026 revenues to reach $19 billion, a 33% increase, and non-GAAP EPS growth in the low- to mid-50% range.
3 days ago · marketbeat.com
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings CallRegeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.
3 days ago · 247wallst.com
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFsRegeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
3 days ago · zacks.com
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
3 days ago · zacks.com
Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesRegeneron (REGN) came out with quarterly earnings of $20.07 per share, beating the Zacks Consensus Estimate of $16.08 per share. This compares to earnings of $11.83 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove REGN